"Rising Ozempic and Weight-Loss Drug Use to Drive US Economic Growth"
TL;DR Summary
Goldman Sachs forecasts a potential 1% jump in US GDP if 60 million Americans take GLP-1 weight loss drugs by 2028, citing the economic burden of poor health on labor supply and productivity. The drugs, such as Ozempic and Wegovy, have shown promising results in weight loss and improving health outcomes for patients with type 2 diabetes and obesity. With the US obesity rate at around 40%, the potential widespread use of these drugs could lead to significant economic spillovers, including increased productivity and GDP growth.
- More Americans taking Ozempic will boost US economy growth outlook Business Insider
- Weight-loss drugs could boost US GDP by 1% in coming years, Goldman says Reuters
- Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs The Guardian US
- Pharmalittle: We're reading about a pharma job slowdown, diet drugs boosting GDP, and more STAT
- Multi-billion dollar weight loss drug market causes race to pharmacy FOX 59 Indianapolis
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
85%
579 → 86 words
Want the full story? Read the original article
Read on Business Insider